9mw2821
mAbexperimentalADC
Clinical trial activity
12 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
10
Phase 3
3
Phase 4
0
Earliest trial started Jun 11, 2022 (NCT05216965)
Timeline
Indications
Mechanism of action
- Nectin-4BINDING AGENT
NECTIN4 binding agent
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07045311 | Phase 2 | Sep 17, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT06947226 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Mabwell, Zhengzhou University |
| NCT06926998 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2025 | Chinese Academy of Medical Sciences, Mabwell |
| NCT06823427 | Phase 2 | Jan 17, 2025 | Mabwell |
| NCT06692166 | Phase 3 | Sep 10, 2024 | Mabwell |
| NCT06592326 | Phase 3 | Aug 22, 2024 | Mabwell |
| NCT06492005 | Phase 2 | Jul 31, 2024 | Mabwell |
| NCT06551233 | Phase 1 | Apr 22, 2024 | Nanjing University |
| NCT06196736 | Phase 3 | Dec 29, 2023 | Mabwell |
| NCT06079112 | Phase 1/Phase 2 (Phase 2) | Oct 10, 2023 | Mabwell |
| NCT05773937 | Phase 1 | Jun 21, 2022 | Mabwell |
| NCT05216965 | Phase 1/Phase 2 (Phase 2) | Jun 11, 2022 | Mabwell |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mabwell | For profit | 10 | 10 | 3 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1